Phase 2b trial analyzes serum potassium changes with interventions in CKD patients, suggesting potential benefits.
Despite clinical benefits of sodium glucose co-transporter-2 inhibitors (SGLT2i), recommended by current guidelines for the treatment of chronic kidney disease (CKD), there is still an unmet need for managing residual risk of disease progression. Balcinrenone is a novel, non-steroidal mineralocorticoid receptor antagonist (MRA) expected to maintain the cardio-renal benefits of MR antagonists with a reduced risk of hyperkalaemia based on pre-clinical data. Balcinrenone in combination with dapagliflozin may provide complementary and additive kidney and cardiovascular protection.
No takes yet. Share an insight, caveat, or question.
Heerspink et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: